Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 20/20 | 0.82 |
| ▸ | PARP1 | P09874 | 20/20 | 0.82 |
| ▸ | TNKS2 | Q9H2K2 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702018 | 0.90 | TNKS (1.00) | TNKSPARP1TNKS2 | |
| SCHEMBL16711548 | 0.82 | TNKS (1.00) | TNKSPARP1TNKS2 | |
| SCHEMBL16701627 | 0.82 | TNKS (1.00) | TNKSPARP1TNKS2 | |
| SCHEMBL16711553 | 0.82 | TNKS (1.00) | TNKSPARP1TNKS2 | |
| Hydrochloric Acid SCHEMBL18037763 | 0.82 | TNKS (0.98) | TNKSPARP1TNKS2 | |
| SCHEMBL16711552 | 0.82 | TNKS (1.00) | TNKSPARP1TNKS2 | |
| SCHEMBL16701409 | 0.81 | TNKS (1.00) | TNKSPARP1TNKS2 | |
| Hydrochloric Acid SCHEMBL18037770 | 0.81 | TNKS (0.98) | TNKSPARP1TNKS2 | |
| SCHEMBL29493091 | 0.81 | TNKS (1.00) | TNKSPARP1TNKS2 | |
| SCHEMBL16711636 | 0.80 | TNKS (1.00) | TNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066099-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | Eli Lilly and Company (US) | 2016-09-14 | — | — | EP | claimed |
| WO-2015069512-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-14 | — | — | WO | claimed |
| EP-3836929-A1 | METHODS OF TREATING LIVER DISEASES | Camp4 Therapeutics Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2020-07-02 | — | — | US | disclosed |
| CN-111094581-A | Methods of treating liver disease | 4阵营疗法公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2020037069-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-3066099-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | Eli Lilly and Company (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069512-A1 | PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | LIPC, PNPLA2, PNLIP | TNKS 2073/4885PARP1 2560/4885TNKS2 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.